Comparing Generic and Brand Name Cisplatin and Identifying the Risk of Hyponatremia
the Cancer Therapy Advisor take:
With growing concerns regarding the cost of cancer care and increased planning and discussion regarding cost issues in healthcare, the use of generic drugs is considered to be a key element of reducing costs. Despite this, the market share of generic drugs is low.
In addition, while most general drugs contain identical active ingredients compared to brand name drugs, that is not true for every generic drugs. When active ingredients vary between generic and brand name drugs, toxicity profiles can be affected.
Researchers in Okayama, Japan, conducted a retrospective analysis to identify the number of patients who had hyponatremia after receiving either the brand name cisplatin or a generic version of cisplatin. The researchers reviewed 79 records in total, 53 records of patients who received brand name cisplatin and 26 records of patients who received generic cisplatin.
The researchers used the records to compare the number of patients who had hyponatremia and renal toxicity. The toxicities were graded the Common Terminology Criteria for Adverse Events, version 4.0 and differences between groups were evaluated using the Student’s t-test, and the odds ratio for hyponatremia was estimated via logistic regression analysis. The researchers found that patients in both groups had significantly increased serum creatinine levels after they received either form of chemotherapy.
However, grade 3 or higher hyponatremia was seen in 30.7% of the generic cisplatin group compared with the 15.1% in the brand name cisplatin group. A multivariate analysis was conducted and revealed that the use of generic cisplatin increased the incidence of hyponatremia (odds ratio=5.661, 95% confidence interval 1.403, 22.839; P=0.015).
The researchers concluded that oncologists should be aware of the potential for an increased risk of hyponatremia in patients receiving generic cisplatin.
Retrospective analysis to identify the number of patients who had hyponatremia after receiving either the brand name cisplatin or a generic.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer